We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

28 hedge funds and large institutions have $345K invested in Alaunos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more capital invested

Capital invested by funds: $103K → $345K (+$241K)

0.09% less ownership

Funds ownership: 4.42%4.33% (-0.09%)

3% less funds holding

Funds holding: 2928 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
28
Holders Change
-1
Holders Change %
-3.45%
% of All Funds
0.37%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$15 +$9 +3 New
TC
27
Truvestments Capital
Florida
$5
WPA
28
West Paces Advisors
Georgia
-$15 -10 Closed
PA
29
PSI Advisors
Florida
-$9 -6 Closed
T
30
Tidemark
California
-$3 -2 Closed

TCRT Hedge Fund Activity: Q2 2025 in Review

28 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2025, worth a combined $345K — up 233% from $103K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of TCRT and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 3 added.

The largest buyer was Steward Partners Investment Advisory, adding an estimated $3.01K. The largest seller was UBS Group, cutting an estimated $3.17K.

  • 28 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2025, down from 29 in Q1 2025.
  • Funds reported $345K of Alaunos Therapeutics stock for Q2 2025, up 233% quarter-over-quarter.
  • 3 funds opened new Alaunos Therapeutics positions in Q2 2025 and 4 closed out, a net change of -1 holder.
  • The largest Alaunos Therapeutics buyer in Q2 2025 was Steward Partners Investment Advisory, an estimated $3.01K added.
  • The largest Alaunos Therapeutics seller in Q2 2025 was UBS Group, an estimated $3.17K sold.

Based on aggregated 13F filings for Q2 2025.